World Glaucoma Week: The Future of Glaucoma Management
USA Today Highlights Alcon Innovations During World Glaucoma Week
Mar 12, 2018
Alcon appeared in USA Today’s special report on “Vision & Hearing” in March around World Glaucoma Week. The report examines the gaps in current treatment options for glaucoma and spotlights innovative glaucoma technology called microinvasive glaucoma surgery (MIGS) that is bringing hope for many patients for better disease management and, potentially, a life with reduced dependence on daily prescription eye drops. The report highlights CyPass® Micro-Stent, a MIGS option that is available nationwide for patients with mild to moderate primary open-angle glaucoma undergoing cataract surgery.
From the article, What Does the Future of Glaucoma Management Look Like?: “Over the last decade, we have seen a tremendous amount of innovation in other ophthalmic areas such as cataracts, but less so with glaucoma,” says Jim Di Filippo, Vice President and General Manager at Alcon. “We are always looking for new solutions to address unmet medical needs and the CyPass® Micro-Stent is an important option that is less invasive than traditional glaucoma surgery, with the potential to help reduce patient dependence on prescription eye drops.”
Visit Alcon’s new online tool - MyCyPass.com - for more information about how you can address your glaucoma at the same time as cataract surgery and find a CyPass® Micro-Stent surgeon in your local area
Important information about the CyPass® Micro-Stent
The CyPass® Micro-Stent is a prescription medical device that is used to reduce intraocular pressure (IOP) in patients with mild to moderate primary open-angle glaucoma who are undergoing cataract surgery. The CyPass® Micro-Stent should not be used in patients with other types of glaucoma, or in patients whose eye anatomy or condition is unusual (for instance, if the area in the patient’s eye is too narrow to implant the CyPass® Micro-Stent, or if there is a condition that may prevent the eye surgeon from seeing where it will be implanted). If IOP is not adequately maintained after implantation of a CyPass® Micro-Stent, additional therapy may be needed for IOP control.
As with any surgery, there are risks and potential complications associated with routine cataract surgery and implantation of a CyPass® Micro-Stent. The risks of CyPass® Micro-Stent implantation with cataract surgery are similar to the risks of having cataract surgery alone; however, there are some additional risks associated with CyPass® Micro-Stent implantation. There is a small risk that the CyPass® Micro-Stent implantation will not be successful or the device may not be properly positioned. Other risks that may be related to use of the CyPass® Micro-Stent include bleeding during surgery, inflammation, tissue trauma, fluid collection in the back of the eye, changes in eye pressure that could affect vision, the feeling that there is something in the eye, eye pain, glaucoma disease progression, or the IOL may move from its original position. Additional surgeries may be needed to address these risks.
Talk to your eye doctor about the risks and benefits of the CyPass® Micro-Stent.